Benzo[a]pyrene inhibits osteoclastogenesis by affecting RANKL-induced activation of NF-κB

Biochemical Pharmacology

Volumn 75, Issue 10, 2008, Pages 2034-2044

  Voronov, I ^a,b   Li, K ^b   Tenenbaum, H C ^a,b   Manolson, M F ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

AhR; Benzo a pyrene; NF B; Osteoclasts; RANKL

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; CIGARETTE SMOKE; CYTOCHROME P450 1B1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; MACROPHAGE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OSTEOCLAST; POLLUTANT; PRIORITY JOURNAL; REPORTER GENE; SIGNAL TRANSDUCTION; SMOG;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BENZO(A)PYRENE; CARCINOGENS, ENVIRONMENTAL; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION; GLIOTOXIN; MICE; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-MYC; RANK LIGAND; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; THIOPHENES;

EID: 42649128694     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.02.025     Document Type: Article

References (51)

1. Blanco G.A., and Cooper E.L. Immune systems, geographic information systems (GIS), environment and health impacts. J Toxicol Environ Health B Crit Rev 7 (2004) 465-480
2. Pitts Jr. J.N., Van Cauwenberghe K.A., Grosjean D., Schmid J.P., Fitz D.R., Belser W.L., et al. Atmospheric reactions of polycyclic aromatic hydrocarbons: facile formation of mutagenic nitro derivatives. Science 202 (1978) 515-519
3. Hankinson O. Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch Biochem Biophys 433 (2005) 379-386
4. Mimura J., and Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 1619 (2003) 263-268
5. Denison M., Pandini A., Nagy S., Baldwin E., and Bonati L. Ligand binding and activation of the Ah receptor. Chem Biol Interact 141 (2002) 3-24
6. Haverstock B., and Mandracchia V. Cigarette smoking and bone healing: implications in foot and ankle surgery. J Foot Ankle Surg 37 (1998) 69-74
7. Olofsson H., Byberg L., Mohsen R., Melhus H., Lithell H., and Michaelsson K. Smoking and the risk of fracture in older men. J Bone Miner Res 20 (2005) 1208-1215
8. Tian Y., Rabson A., and Gallo M. Ah receptor and NF-kappaB interactions: mechanisms and physiological implications. Chem Biol Interact 141 (2002) 97-115
9. Bock K.W., and Kohle C. Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. Biochem Pharmacol 72 (2006) 393-404
10. Boyle W., Simonet W., and Lacey D. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
11. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96 (1999) 3540-3545
12. Hayden M.S., and Ghosh S. Signaling to NF-kappaB. Genes Dev 18 (2004) 2195-2224
13. Martin L., and Byrd S. Rapid communication: effects of tobacco processing on the quantity of benzo[a]pyrene in mainstream smoke. J Toxicol Environ Health 66 (2003) 1283-1286
14. Besaratinia A., Kleinjans J.C., and Van Schooten F.J. Biomonitoring of tobacco smoke carcinogenicity by dosimetry of DNA adducts and genotyping and phenotyping of biotransformational enzymes: a review on polycyclic aromatic hydrocarbons. Biomarkers 7 (2002) 209-229
15. Voronov I., Heersche J.N., Casper R.F., Tenenbaum H.C., and Manolson M.F. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration. Biochem Pharmacol 70 (2005) 300-307
16. Nelson D.E., Ihekwaba A.E., Elliott M., Johnson J.R., Gibney C.A., Foreman B.E., et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306 (2004) 704-708
17. Hoffmann A., Levchenko A., Scott M.L., and Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298 (2002) 1241-1245
18. Zou W., Amcheslavsky A., Takeshita S., Drissi H., and Bar-Shavit Z. TNF-alpha expression is transcriptionally regulated by RANK ligand. J Cell Physiol 202 (2005) 371-378
19. Beg A.A., Sha W.C., Bronson R.T., and Baltimore D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev 9 (1995) 2736-2746
20. Pahl H.L., Krauss B., Schulze-Osthoff K., Decker T., Traenckner E.B., Vogt M., et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med 183 (1996) 1829-1840
21. Ozaki K., Takeda H., Iwahashi H., Kitano S., and Hanazawa S. NF-kappaB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett 410 (1997) 297-300
22. Herfarth H., Brand K., Rath H.C., Rogler G., Scholmerich J., and Falk W. Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin Exp Immunol 120 (2000) 59-65
23. Kishore N., Sommers C., Mathialagan S., Guzova J., Yao M., Hauser S., et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem 278 (2003) 32861-32871
24. Hogan P.G., Chen L., Nardone J., and Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17 (2003) 2205-2232
25. Duyao M.P., Buckler A.J., and Sonenshein G.E. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci U S A 87 (1990) 4727-4731
26. Battaglino R., Kim D., Fu J., Vaage B., Fu X., and Stashenko P. c-myc is required for osteoclast differentiation. J Bone Miner Res 17 (2002) 763-773
27. Tian Y., Ke S., Denison M.S., Rabson A.B., and Gallo M.A. Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J Biol Chem 274 (1999) 510-515
28. Ruby C.E., Leid M., and Kerkvliet N.I. 2 3,7 8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: p50 homodimer activation is not affected. Mol Pharmacol 62 (2002) 722-728
29. Takatsuna H., Asagiri M., Kubota T., Oka K., Osada T., Sugiyama C., et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res 20 (2005) 653-662
30. Puga A., Barnes S.J., Chang C., Zhu H., Nephew K.P., Khan S.A., et al. Activation of transcription factors activator protein-1 and nuclear factor-kappaB by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Pharmacol 59 (2000) 997-1005
31. Banerjee R., Caruccio L., Zhang Y.J., McKercher S., and Santella R.M. Effects of carcinogen-induced transcription factors on the activation of hepatitis B virus expression in human hepatoblastoma HepG2 cells and its implication on hepatocellular carcinomas. Hepatology 32 (2000) 367-374
32. Ding J., Wu K., Zhang D., Luo W., Li J., Ouyang W., et al. Activation of both nuclear factor of activated T cells and inhibitor of nuclear factor-kappaB kinase beta-subunit-/nuclear factor-kappaB is critical for cyclooxygenase-2 induction by benzo[a]pyrene in human bronchial epithelial cells. Cancer Sci 98 (2007) 1323-1329
33. Camacho I.A., Singh N., Hegde V.L., Nagarkatti M., and Nagarkatti P.S. Treatment of mice with 2,3,7 8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-kappaB and expression of Fas ligand in thymic stromal cells and consequent apoptosis in T cells. J Immunol 175 (2005) 90-103
34. Warren G.W., Poloyac S.M., Gary D.S., Mattson M.P., and Blouin R.A. Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 288 (1999) 945-950
35. Ke S., Rabson A.B., Germino J.F., Gallo M.A., and Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem 276 (2001) 39638-39644
36. Bleau A.M., Maurel P., Pichette V., Leblond F., and du Souich P. Interleukin-1beta, interleukin-6, tumour necrosis factor-alpha and interferon-gamma released by a viral infection and an aseptic inflammation reduce CYP1A1 1A2 and 3A6 expression in rabbit hepatocytes. Eur J Pharmacol 473 (2003) 197-206
37. Morgan E.T. Regulation of cytochrome p450 by inflammatory mediators: why and how?. Drug Metab Dispos 29 (2001) 207-212
38. Wada T., Nakashima T., Hiroshi N., and Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12 (2006) 17-25
39. Tanaka S., Nakamura K., Takahasi N., and Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208 (2005) 30-49
40. Adhikari A., Xu M., and Chen Z.J. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26 (2007) 3214-3226
41. Deng L., Wang C., Spencer E., Yang L., Braun A., You J., et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103 (2000) 351-361
42. Ohtake F., Baba A., Takada I., Okada M., Iwasaki K., Miki H., et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446 (2007) 562-566
43. Wu P., and Wang P. Per-Arnt-Sim domain-dependent association of cAMP-phosphodiesterase 8A1 with IkappaB proteins. Proc Natl Acad Sci U S A 101 (2004) 17634-17639
44. Zhang L., Savas U., Alexander D.L., and Jefcoate C.R. Characterization of the mouse Cyp1B1 gene. Identification of an enhancer region that directs aryl hydrocarbon receptor-mediated constitutive and induced expression. J Biol Chem 273 (1998) 5174-5183
45. Zheng W., and Jefcoate C.R. Steroidogenic factor-1 interacts with cAMP response element-binding protein to mediate cAMP stimulation of CYP1B1 via a far upstream enhancer. Mol Pharmacol 67 (2005) 499-512
46. Singh S., Casper R., Fritz P., Sukhu B., Ganss B., Girard B.J., et al. Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol 167 (2000) 183-195
47. Naruse M., Otsuka E., Naruse M., Ishihara Y., Miyagawa-Tomita S., and Hagiwara H. Inhibition of osteoclast formation by 3-methylcholanthrene, a ligand for arylhydrocarbon receptor: suppression of osteoclast differentiation factor in osteogenic cells. Biochem Pharmacol 67 (2004) 119-127
48. Bruno R.D., and Njar V.C. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem 15 (2007) 5047-5060
49. Tsuchiya Y., Nakajima M., and Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227 (2005) 115-124
50. Kim J.H., Sherman M.E., Curriero F.C., Guengerich F.P., Strickland P.T., and Sutter T.R. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol 199 (2004) 210-219
51. Pacifici R. Estrogen deficiency T cells and bone loss. Cell Immunol (2007)